EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

Elizabeth M Williamson iD, Thomas Brendler iD

Phytotherapy Research · 2026-08 · 40 (8) · 4792-4801

DOI: 10.1002/ptr.70090 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Phytotherapy Research, online erschienen am 18.09.2025. Verfasst von Elizabeth M Williamson und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Reading, Reading, UK. Hauptthemen laut MEDLINE: Withania, Plant Extracts. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The preclinical evidence for the safety of ashwagandha ( Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports. Most studies and reviews conclude that AS is a remarkably safe herb, but cases of liver toxicity, mainly reversible cholestasis or severe jaundice and pruritus, have been reported without being predicted by preclinical evidence. Further work is needed to clarify the constituents responsible and patient‐related issues surrounding them. Several constituents, such as withaferin‐A, have demonstrable antitumorigenic effects in animal models of liver cancer and injury induced by ischemia, cytotoxic drugs, and radiotherapy. AS has not shown genotoxicity or mutagenicity in standard tests; on the contrary, it was protective against chromosome abnormalities or micronuclei formation induced by known clastogenic agents. A folkloric reputation for inducing abortion or sterility is not borne out of preclinical experiments, and rare reports of cardiotoxicity could not be substantiated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WithaniaPlant ExtractsAnimalsHumansWithanolides

Stichwörter der Autor:innen

Withaniaadaptogenashwagandhapreclinical investigationssafety

Substanzen

Plant ExtractsAshwagandhaWithanolideswithaferin A

Autor:innen und Institutionen

  • School of Pharmacy, University of Reading, Reading, UK.
  • Department of Botany and Plant Biotechnology, University of Johannesburg, Johannesburg, South Africa.
  • Department of Pharmaceutical Sciences, Pharmacognosy Institute, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.
  • National Center for Naturopathic Medicine, Southern Cross University, East Lismore, Australia.

ORCID-Profile: Elizabeth M Williamson, Thomas Brendler

Zitieren

APA

Williamson, E. M., & Brendler, T. (2026). Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review. Phytotherapy Research, 40(8), 4792-4801. https://doi.org/10.1002/ptr.70090

Vancouver

Williamson EM, Brendler T. Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review. Phytotherapy Research. 2026;40(8):4792-4801. doi:10.1002/ptr.70090

BibTeX
@article{Williamson2026,
  author = {Williamson, Elizabeth M and Brendler, Thomas},
  title = {Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review},
  journal = {Phytotherapy Research},
  year = {2026},
  volume = {40},
  number = {8},
  pages = {4792--4801},
  doi = {10.1002/ptr.70090}
}
Kostenlos starten →